Successful dual-valve transcatheter therapy for severe aortic stenosis and mitral regurgitation

Transcatheter valve therapies have emerged to be a feasible alternative to patients with significant valvular diseases who are deemed too high risk for conventional open-heart surgery. Studies have demonstrated that Transcatheter Aortic Valve Implantation (TAVI) shows a mortality benefit over conservative management and non-inferior to surgical aortic valve replacement in patients with symptomatic severe aortic stenosis [1,2]. For mitral regurgitation, edge-to-edge mitral valve repair using MitraClip system, when compared with conventional surgery, has been associated with superior safety and similar clinical outcome [3]. However, unlike performing an open heart operation for concomitant aortic stenosis/regurgitation and mitral regurgitation, little is known about using transcatheter valve therapy to treat concomitant valve pathologies